59 related articles for article (PubMed ID: 28238045)
21. Nonparametric bounds for the survivor function under general dependent truncation.
Qian J; Betensky RA
Scand Stat Theory Appl; 2023 Mar; 50(1):327-357. PubMed ID: 37179756
[TBL] [Abstract][Full Text] [Related]
22. [Dependent censoring].
Gran JM; Stensrud MJ
Tidsskr Nor Laegeforen; 2024 Jan; 144(1):. PubMed ID: 38258729
[No Abstract] [Full Text] [Related]
23. On High-Dimensional Covariate Adjustment for Estimating Causal Effects in Randomized Trials with Survival Outcomes.
Dai R; Zheng C; Zhang MJ
Stat Biosci; 2023 Apr; 15(1):242-260. PubMed ID: 37143607
[TBL] [Abstract][Full Text] [Related]
24. The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.
Dong G; Mao L; Huang B; Gamalo-Siebers M; Wang J; Yu G; Hoaglin DC
J Biopharm Stat; 2020 Sep; 30(5):882-899. PubMed ID: 32552451
[TBL] [Abstract][Full Text] [Related]
25. A causal framework for classical statistical estimands in failure-time settings with competing events.
Young JG; Stensrud MJ; Tchetgen Tchetgen EJ; Hernán MA
Stat Med; 2020 Apr; 39(8):1199-1236. PubMed ID: 31985089
[TBL] [Abstract][Full Text] [Related]
26. A note on competing risks in survival data analysis.
Satagopan JM; Ben-Porat L; Berwick M; Robson M; Kutler D; Auerbach AD
Br J Cancer; 2004 Oct; 91(7):1229-35. PubMed ID: 15305188
[TBL] [Abstract][Full Text] [Related]
27. Adverse events in single-arm clinical trials with non-fatal time-to-event efficacy endpoint: from clinical questions to methods for statistical analysis.
Tassistro E; Bernasconi DP; Valsecchi MG; Antolini L
BMC Med Res Methodol; 2024 Jan; 24(1):3. PubMed ID: 38172810
[TBL] [Abstract][Full Text] [Related]
28. Estimation of the cumulative incidence function under multiple dependent and independent censoring mechanisms.
Lok JJ; Yang S; Sharkey B; Hughes MD
Lifetime Data Anal; 2018 Apr; 24(2):201-223. PubMed ID: 28238045
[TBL] [Abstract][Full Text] [Related]
29. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.
Willems S; Schat A; van Noorden MS; Fiocco M
Stat Methods Med Res; 2018 Feb; 27(2):323-335. PubMed ID: 26988930
[TBL] [Abstract][Full Text] [Related]
30. Parametric likelihood inference for interval censored competing risks data.
Hudgens MG; Li C; Fine JP
Biometrics; 2014 Mar; 70(1):1-9. PubMed ID: 24400873
[TBL] [Abstract][Full Text] [Related]
31. Limitation of inverse probability-of-censoring weights in estimating survival in the presence of strong selection bias.
Howe CJ; Cole SR; Chmiel JS; Muñoz A
Am J Epidemiol; 2011 Mar; 173(5):569-77. PubMed ID: 21289029
[TBL] [Abstract][Full Text] [Related]
32. Association analysis of successive events data in the presence of competing risks.
Chen X; Cheng Y; Frank E; Kupfer DJ
Stat Methods Med Res; 2018 Jun; 27(6):1661-1682. PubMed ID: 27647813
[TBL] [Abstract][Full Text] [Related]
33. Evaluating predictors of competing risk outcomes when censoring depends on time-dependent covariates, with application to safety and efficacy of HIV treatment.
Lok JJ; Hughes MD
Stat Med; 2016 Jun; 35(13):2183-94. PubMed ID: 26763556
[TBL] [Abstract][Full Text] [Related]
34. Establishment, retention, and loss to follow-up in outpatient HIV care.
Fleishman JA; Yehia BR; Moore RD; Korthuis PT; Gebo KA;
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):249-59. PubMed ID: 22531758
[TBL] [Abstract][Full Text] [Related]
35. Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-treated HIV-infected persons: an AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysis.
Krishnan S; Wu K; Smurzynski M; Bosch RJ; Benson CA; Collier AC; Klebert MK; Feinberg J; Koletar SL;
HIV Clin Trials; 2011; 12(4):190-200. PubMed ID: 22044855
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
